Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-04-24Clinical Trial Update: The Effect of tDCS on Schizophrenia With Negative Symptoms [NA]
The clinical trial examining transcranial direct current stimulation (tDCS) for negative symptoms in schizophrenia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-03-12Clinical Trial Update: Lifestyle MIND- Feasibility of Wait-list Control [NA]
A feasibility trial of a Lifestyle MIND intervention for individuals with Type 2 diabetes mellitus and serious mental illness (including sch…
-
CLINICAL_TRIALS withdrawal · 2026-01-28Clinical Trial Update: Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department [Phase 4]
A Phase 4 pilot trial of BXCL501 (sublingual dexmedetomidine) for agitation in the emergency department, including schizophrenia-spectrum an…
-
CLINICAL_TRIALS withdrawal · 2025-12-08Clinical Trial Update: Pharmacologic Treatment in Legal Offenders With Schizophrenia, a Prospective Observational Mirror Image Study.
A pharmacologic treatment trial in legal offenders with schizophrenia has been withdrawn. The study is no longer in progress.
-
EMA withdrawal · 2025-09-23EMA Withdrawn: Olanzapine Apotex (olanzapine) — Apotex Europe BV
The EMA has withdrawn Olanzapine Apotex, an olanzapine product from Apotex Europe BV.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-07-22Clinical Trial Update: Lost Children Society (LCS), Online Therapeutic Tabletop Role-playing Game for Early-onset Schizophrenia Patients [NA]
The clinical trial investigating an online therapeutic tabletop game for early-onset schizophrenia has been withdrawn; no study results are …
-
CLINICAL_TRIALS withdrawal · 2025-07-14Clinical Trial Update: Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia [Phase 2]
A Phase 2 clinical trial of vildagliptin for treating antipsychotic-induced dyslipidemia in schizophrenia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-04-08Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder [Phase 3]
A Phase 3 trial evaluating the safety and tolerability of Lyndra's long-acting oral risperidone (LYN-005) in schizophrenia or schizoaffectiv…
-
CLINICAL_TRIALS withdrawal · 2025-03-21Clinical Trial Update: Evaluation Study of New Compounds With Potential Use in Schizophrenia [Phase 1]
Phase 1 clinical trial evaluating new compounds for schizophrenia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-03-07Clinical Trial Update: How Can a Driving Virtual Reality Tool Improve Quality of Life and Social Autonomy in Patients With Schizophrenia [NA]
The clinical trial evaluating a driving-related virtual reality tool to improve quality of life and social autonomy in schizophrenia has bee…
-
CLINICAL_TRIALS withdrawal · 2024-12-09Clinical Trial Update: The Sub-Sero Study [Phase 2]
Phase 2 trial titled 'The Sub-Sero Study' sponsored by Bjorn H. Ebdrup has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-11-12Clinical Trial Update: Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia [Phase 3]
A Phase 3 trial evaluating valbenazine as an adjunctive treatment for schizophrenia has been terminated.
-
CLINICAL_TRIALS withdrawal · 2024-10-15Clinical Trial Update: HDAC Inhibitor Augmentation to Clozapine [EARLY_Phase 1]
An early-phase 1 clinical trial evaluating HDAC inhibitor augmentation to Clozapine for schizophrenia was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-08-22Clinical Trial Update: REtinal and VIsual Cortical Response in Early PSYchosis [NA]
The clinical trial 'REtinal and Visual Cortical Response in Early PSYchosis' has been terminated. It studied retinal and visual cortical res…
-
CLINICAL_TRIALS withdrawal · 2024-08-07Clinical Trial Update: Application of Group Interpersonal Psychotherapy (IPT-G) to Family Members Caring for Patients With Schizophrenia [NA]
A withdrawn clinical trial investigating Group Interpersonal Psychotherapy (IPT-G) for family members caring for patients with schizophrenia…
-
CLINICAL_TRIALS withdrawal · 2024-07-30Clinical Trial Update: tDCS and Executive Function Training for Schizophrenia [NA]
A clinical trial evaluating transcranial direct current stimulation (tDCS) with executive function training for schizophrenia has been withd…
-
CLINICAL_TRIALS withdrawal · 2024-06-24Clinical Trial Update: An Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Amisulpride in Treating Patients With Schizophrenia and Schizoaffective Disorder Who Have Treatment-Resistant Positive Symptoms [NA]
The UCLA-sponsored open-label, single-arm trial of amisulpride for treatment-resistant schizophrenia and schizoaffective disorder has been w…
-
CLINICAL_TRIALS withdrawal · 2024-05-09Clinical Trial Update: Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen® [Phase 2, Phase 3]
An adaptive Phase II/III trial of NaBen for schizophrenia has been terminated.
-
EMA withdrawal · 2023-07-07EMA Application withdrawn: Asimtufii (aripiprazole monohydrate) — Otsuka Pharmaceutical Netherlands B.V.
The EMA has withdrawn the application for Asimtufii (aripiprazole monohydrate) by Otsuka Pharmaceutical Netherlands B.V. for schizophrenia.
-
CLINICAL_TRIALS withdrawal · 2021-06-03Clinical Trial Update: SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia [Phase 3]
Phase 3 study SPD489 as adjunctive treatment for negative symptoms of schizophrenia was withdrawn.
-
EMA withdrawal · 2020-10-22EMA Application withdrawn: Abilify MyCite (aripiprazole) — Otsuka Pharmaceutical Netherlands B.V.
The EMA has withdrawn the application for Abilify MyCite (aripiprazole) by Otsuka Pharmaceutical Netherlands B.V.
-
CLINICAL_TRIALS withdrawal · 2019-04-24Clinical Trial Update: Alleviating the Metabolic Side Effects of Antipsychotic Medications [Phase 4]
A Phase 4 clinical trial investigating methods to alleviate metabolic side effects of antipsychotic medications has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2019-01-17Clinical Trial Update: Sodium Butyrate For Improving Cognitive Function In Schizophrenia [Phase 2, Phase 3]
A clinical trial evaluating sodium butyrate for improving cognitive function in schizophrenia has been withdrawn from Phase 2/Phase 3.
-
CLINICAL_TRIALS withdrawal · 2018-07-18Clinical Trial Update: Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With Olanzapine [NA]
A clinical trial investigating whether green tea can prevent olanzapine-associated weight gain and dyslipidemia in patients with bipolar dis…
-
CLINICAL_TRIALS withdrawal · 2018-04-05Clinical Trial Update: Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia [Phase 4]
The Phase 4 clinical trial examining clonazepam effects on brain oscillations and cognition in schizophrenia-related conditions has been wit…